A5026810806- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Microscopic Colitis
- T-cell and B-cell Immunology
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Hematological disorders and diagnostics
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Forensic Toxicology and Drug Analysis
- Viral gastroenteritis research and epidemiology
- Dermatological and COVID-19 studies
- Clostridium difficile and Clostridium perfringens research
- Hidradenitis Suppurativa and Treatments
- Acute Lymphoblastic Leukemia research
- Pneumocystis jirovecii pneumonia detection and treatment
- Youth, Drugs, and Violence
- Immunodeficiency and Autoimmune Disorders
- Inflammatory Biomarkers in Disease Prognosis
- Medical History and Innovations
- Bone and Joint Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Reproductive System and Pregnancy
- Endometrial and Cervical Cancer Treatments
Universidade Federal de Minas Gerais
2008-2025
Hospital das Clínicas da Universidade Federal de Minas Gerais
2019-2025
To provide guidelines on the coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated rheumatic diseases (IMRD) to rheumatologists considering specific scenarios of daily practice based shared-making decision (SMD) process.
To evaluate factors associated with COVID-19 severity outcomes in patients systemic lupus erythematosus (SLE).This was a cross-sectional analysis of baseline data prospective, multi-stage cohort study-"The ReumaCoV Brazil"-designed to monitor immune-mediated rheumatologic disease (IMRD) during the SARS-CoV-2 pandemic. SLE adult were compared those without COVID-19. activity evaluated by patient global assessment (PGA) and Disease Activity Index 2000 (SLEDAI-2K).604 included, 317 (52.4%) 287...
Identification of infection in patients with systemic lupus erythematosus (SLE) is a major challenge clinical practice.This medical records review study evaluated markers, including the performance C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte (PLR) diagnosis SLE patients.One hundred four hospitalized between 2014 2018 were allocated into 3 groups, namely, infection, disease activity, isolated activity. Groups compared relation to laboratory variables....
CONCLUSIONPatients with SLE and COVID-19 had higher disease activity indices a incidence of new manifestations than the control group.Traditional risk factors for poor outcomes in SARS-CoV-2 infection, such as male gender, HBP, pulmonary disease, were also associated flare SLE.
The identification of infection in patients with Systemic Lupus Erythematosus (SLE) is a major challenge clinical practice due to its high frequency, mortality and manifestations that are confused active disease. objective the present study was evaluate markers use C-reactive protein (CRP), neutrophil-lymphocyte (NLR) platelet -lymphocyte (PLR) ratios diagnosis SLE patients.
Macrophage Activation Syndrome (MAS) is a rare life-threatening disorder among the hemophagocitic syndromes, usually triggered by rheumatologic diseases, malignancies and infections, especially Epstein Barr Virus (EBV) Cytomegalovirus (CMV). It consists in deregulated macrophage activation, causing cytokines storm, hemophagocistosis multiple organ dysfunctions, mimicking different conditions, such as sepsis. Treatment should be started suspicion, given high mortality ratio. The authors...
Infectious complications are responsible for about 25% of deaths in patients with Systemic Lupus Erythematous (SLE). In 1998, Petri and contributors estimated that 50% the SLE will develop at least one episode severe infection during disease follow-up. Even though risk atypical infections is increased by chronic immunosuppression, most frequent observed similar to general population. The objective present study analyze a group hospitalized tertiary hospital.